Intravenous thrombolytic therapy for acute ischemic stroke: Weighing the risks and benefits of tissue plasminogen activator

Richard L. Koller; David C. Anderson

doi:10.3810/pgm.1998.04.457

Intravenous thrombolytic therapy for acute ischemic stroke: Weighing the risks and benefits of tissue plasminogen activator

Richard L. Koller, David C. Anderson

Neurology

Research output: Contribution to journal › Review article › peer-review

4 Scopus citations

Abstract

The use of intravenous tPA within 3 hours after acute ischemic stroke has been proved to increase the number of good outcomes. However, tPA is a toxic therapy that carries a substantial risk of intracerebral hemorrhage. To decrease the risk, tPA use must be administered in an intensive care setting and directed by physicians with expertise in diagnosing and managing stroke.

Original language	English (US)
Pages (from-to)	221-231
Number of pages	11
Journal	Postgraduate medicine
Volume	103
Issue number	4
DOIs	https://doi.org/10.3810/pgm.1998.04.457
State	Published - Apr 1998

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access

10.3810/pgm.1998.04.457

OpenUrl availability

Full text

Cite this

@article{9458e43131a7418380e89854b36a6a16,

title = "Intravenous thrombolytic therapy for acute ischemic stroke: Weighing the risks and benefits of tissue plasminogen activator",

abstract = "The use of intravenous tPA within 3 hours after acute ischemic stroke has been proved to increase the number of good outcomes. However, tPA is a toxic therapy that carries a substantial risk of intracerebral hemorrhage. To decrease the risk, tPA use must be administered in an intensive care setting and directed by physicians with expertise in diagnosing and managing stroke.",

author = "Koller, {Richard L.} and Anderson, {David C.}",

year = "1998",

month = apr,

doi = "10.3810/pgm.1998.04.457",

language = "English (US)",

volume = "103",

pages = "221--231",

journal = "Postgraduate medicine",

issn = "0032-5481",

publisher = "Medquest Communications LLC",

number = "4",

}

TY - JOUR

T1 - Intravenous thrombolytic therapy for acute ischemic stroke

T2 - Weighing the risks and benefits of tissue plasminogen activator

AU - Koller, Richard L.

AU - Anderson, David C.

PY - 1998/4

Y1 - 1998/4

N2 - The use of intravenous tPA within 3 hours after acute ischemic stroke has been proved to increase the number of good outcomes. However, tPA is a toxic therapy that carries a substantial risk of intracerebral hemorrhage. To decrease the risk, tPA use must be administered in an intensive care setting and directed by physicians with expertise in diagnosing and managing stroke.

AB - The use of intravenous tPA within 3 hours after acute ischemic stroke has been proved to increase the number of good outcomes. However, tPA is a toxic therapy that carries a substantial risk of intracerebral hemorrhage. To decrease the risk, tPA use must be administered in an intensive care setting and directed by physicians with expertise in diagnosing and managing stroke.

UR - http://www.scopus.com/inward/record.url?scp=0031979949&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031979949&partnerID=8YFLogxK

U2 - 10.3810/pgm.1998.04.457

DO - 10.3810/pgm.1998.04.457

M3 - Review article

C2 - 9553597

AN - SCOPUS:0031979949

SN - 0032-5481

VL - 103

SP - 221

EP - 231

JO - Postgraduate medicine

JF - Postgraduate medicine

IS - 4

ER -

Intravenous thrombolytic therapy for acute ischemic stroke: Weighing the risks and benefits of tissue plasminogen activator

Abstract

UN SDGs

Access

OpenUrl availability

Other files and links

Fingerprint

Cite this